Table 2 Characteristics of the studies according to molecular subtypes
From: Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases
First author | Year | Patients Number | Patient source | Technique | Type of patients | HR estimation | HR(95%CI) of OS | HR(95%CI) of RFS |
|---|---|---|---|---|---|---|---|---|
Vendrell | 2008 | 33 | France | PCR | ER positive BC | Given by author | 1.08 (0.40-2.88) | 1.38 (0.60-3.21) |
Ponzo | 2009 | 60 | Canada | IHC | Basal-like BC | Given by author | NA | 3.02 (0.31-29.30) |
| Â | Â | 447 | Canada | IHC | Nonbasal-like BC | Given by author | NA | 1.49 (0.86-2.62) |
Raghav | 2012 | 64 | USA | RPPA | TNBC | Given by author | NA | 2.36 (0.86-6.51) |
| Â | Â | 140 | USA | RPPA | hormone receptor positive BC | Given by author | 8.28 (1.10-62.59) | 3.44 (1.21-9.81) |
Gonzalez-Angulo | 2013 | 173 | USA | MIP | TNBC | Given by author | NA | 1.33 (0.51-3.43) |
| Â | Â | 583 | USA | MIP | hormone receptor positive BC | Given by author | NA | 1.86 (1.07-3.25) |
| Â | Â | 207 | USA | MIP | HER-2 positive BC | Given by author | NA | 0.92 (0.29-2.95) |
Zagouri | 2013 | 170 | Austria | IHC | TNBC | Given by author | 3.74(1.65-8.46) | 3.43 (1.65-7.12) |
Zagouri | 2014 | 78 | Austria | IHC | ER and HER-2 positive BC | Given by author | 1.32 (0.91-1.90) | 1.22 (0.91-1.63) |
Inanc | 2014 | 97 | Turkey | IHC | TNBC | Given by author | 1.15 (0.54-2.44) | 2.05 (0.96-4.36) |